Evidence map›Paper›PMID 35193469›Full record

ArticleBioengineered2022

AFAP1 antisense RNA 1 promotes retinoblastoma progression by sponging microRNA miR-545-3p that targets G protein subunit beta 1.

Wenting Tang, Li Zhang, Jing Li, Yu Guan

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Non-coding antisense transcripts: fine regulation of gene expression in cancer.Computational and structural biotechnology journal · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wenting TangDepartment of Ophthalmology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Li ZhangDepartment of Ophthalmology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Jing LiDepartment of Ophthalmology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Yu GuanDepartment of Ophthalmology, Nuclear Industry 416th Hospital, Chengdu, China.
First Affiliated Hospital of Chengdu Medical College · CNChina National Nuclear Corporation · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oncogenic role of actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) has been reported in retinoblastoma (RB). However, the underlying regulatory mechanisms remain poorly understood. In this study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting were performed to analyze the expression of AFAP1-AS1, microRNA miR-545-3p, or G protein subunit beta 1 (GNB1). Cell Counting Kit-8 (CCK-8) and Transwell migration assays were used to detect cell proliferation and migration. In addition, caspase-3 activity was monitored by caspase-3 activity assay. Luciferase reporter assays combined with RNA immunoprecipitation (RIP) and pull-down assays were performed to elucidate the target relationship between miR-545-3p and AFAP1-AS1 or GNB1. Xenograft tumor experiments were performed to evaluate RB cell growth

Indexed as

GTP-Binding Protein beta SubunitsMicroRNAsRetinal NeoplasmsRetinoblastomaRNA, AntisenseRNA, Long NoncodingCaspase 3Cell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansProtein SubunitsAFAP1-AS1 long noncoding RNA, humanCaspase 3GNB1 protein, humanGTP-Binding Protein beta SubunitsMicroRNAsMIR545 microRNA, humanProtein SubunitsRNA, AntisenseRNA, Long Noncodingcellule phenotypesceRNAlncRNAretinoblastoma

Identifiers

PMID35193469
PMCPMC8974164
OpenAlexW4213263423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.